Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 772 across all filing types
Latest filing 2025-07-28 Call Transcript
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on July 24, 2025, discussing the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. It includes detailed management commentary, financial highlights, business updates, and a Q&A session with analysts. The presence of a full transcript of the call, including management remarks and participant questions, clearly identifies this as a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or summary, confirming it is not an Earnings Release or Report Publication Announcement. Therefore, the appropriate classification is Call Transcript (CT).
2025-07-28 English
Copy of Newspaper Publication
Regulatory Filings
2025-07-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the availability of the audio recording of an earnings conference call for the quarter ended June 30, 2025. It references the SEBI regulations and provides a link to the recording on the company's website. The document does not contain the transcript itself or detailed financial data, but rather announces the availability of the call recording. Given the content and length (1550 characters), this is an announcement related to a call transcript, not the transcript itself. Therefore, the appropriate classification is Call Transcript (CT) as it pertains to the earnings call content, but since it only announces the recording availability, it aligns best with the Call Transcript category rather than a report publication or regulatory filing. Confidence is high due to clear references to the earnings call and its recording.
2025-07-24 English
Outcome of Board Meeting
Regulatory Filings
2025-07-24 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the receipt of a Certificate of EU GMP Compliance for a manufacturing facility. It includes a press release detailing the certification and company background. The content is an announcement of a regulatory compliance achievement and does not contain financial statements, management discussion, or detailed financial data. The document length is 4187 characters, which is relatively short and primarily serves as a notification. There is no indication that this is a full report or detailed financial filing. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-07-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming earnings conference call for the quarter ended June 30, 2025. It includes details about the call date, time, participants, and dial-in information. The document does not contain any financial results or substantive financial data itself, but rather serves as an announcement of the event where such results will be discussed. The document length is short (2643 characters), and it explicitly states it is an intimation of the earnings conference call, not the call transcript or earnings release itself. Therefore, it fits the category of a Call Transcript announcement or notification. However, since it is only an announcement of the call and not the transcript, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the call. The document is not the transcript or the earnings release itself.
2025-07-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.